Delgocitinib is marketed under the brand name Corectim [1].
What is Corectim used for?
Corectim is a topical Janus kinase (JAK) inhibitor used for the treatment of atopic dermatitis [1]. It is indicated for adults and children aged 12 years and older with moderate to severe atopic dermatitis that has not been adequately controlled with other topical treatments [1].
How does Corectim work?
Delgocitinib, the active ingredient in Corectim, inhibits the activity of JAKs. JAKs are intracellular enzymes that play a role in signaling pathways for cytokines and growth factors involved in inflammation and immune responses [1]. By inhibiting JAKs, delgocitinib reduces the inflammatory processes that contribute to atopic dermatitis [1].
When did Corectim become available?
Corectim was approved in Japan in March 2021 [1].
What are the potential side effects of Corectim?
Common side effects of Corectim include application site reactions such as itching, redness, and stinging [1]. Other potential side effects can involve hair follicle inflammation (folliculitis) and acne [1].
Are there other treatments for atopic dermatitis?
Yes, there are several other treatment options for atopic dermatitis, including topical corticosteroids, topical calcineurin inhibitors, and other systemic therapies depending on the severity of the condition [2].
How does delgocitinib compare to other topical JAK inhibitors?
Delgocitinib is a topical JAK inhibitor specifically approved for atopic dermatitis in some regions. Other topical JAK inhibitors are also available or in development for dermatological conditions, each with its own specific approved indications and safety profiles.
What is the patent status of delgocitinib?
Information regarding the specific patent status and expiry dates for delgocitinib can be found on specialized patent tracking resources [3].
Who developed delgocitinib?
Delgocitinib was developed by Torii Pharmaceutical Co., Ltd. [1].
---
Sources:
1. https://www.drugpatentwatch.com/p/corectim-delgocitinib
2. https://www.drugpatentwatch.com/therapeutic-areas/dermatology/atopic-dermatitis
3. https://www.drugpatentwatch.com/drugs/delgocitinib